Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial by Fakih, Marwan G, Prof, Kopetz, Scott, Prof, Kuboki, Yasutoshi, Prof, Kim, Tae Won, Prof, Munster, Pamela N, Prof, Krauss, John C, Prof, Falchook, Gerald S, Prof, Han, Sae-Won, Prof, Heinemann, Volker, Prof, Muro, Kei, Prof, Strickler, John H, Prof, Hong, David S, Prof, Denlinger, Crystal S, MD, Girotto, Gustavo, Prof, Lee, Myung-Ah, Prof, Henary, Haby, MD, Tran, Qui, PhD, Park, Joseph K, MD, Ngarmchamnanrith, Gataree, MD, Prenen, Hans, Prof, Price, Timothy J, Prof

Get full text

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUB... by Powles, Thomas, Prof, van der Heijden, Michiel S, MD, Castellano, Daniel, MD, Galsky, Matthew D, Prof, Loriot, Yohann, MD, Petrylak, Daniel P, Prof, Ogawa, Osamu, Prof, Park, Se Hoon, Prof, Lee, Jae-Lyun, Prof, De Giorgi, Ugo, MD, Bögemann, Martin, Prof, Bamias, Aristotelis, Prof, Eigl, Bernhard J, MD, Gurney, Howard, Prof, Mukherjee, Som D, Prof, Fradet, Yves, Prof, Skoneczna, Iwona, MD, Tsiatas, Marinos, MD, Novikov, Andrey, MD, Suárez, Cristina, MD, Fay, André P, Prof, Duran, Ignacio, MD, Necchi, Andrea, MD, Wildsmith, Sophie, PhD, He, Philip, PhD, Angra, Natasha, PharmD, Gupta, Ashok K, MD, Levin, Wendy, MD, Bellmunt, Joaquim, Prof

Get full text